Activating the immunity within the tumor using viroimmunotherapy: Delta-24-RGD oncolytic adenovirus armed with the immunopositive regulator GITRL

Development of a novel class of cGAS agonists to trigger STING pathway-dependent innate immune responses against Glioblastoma

Trial in Progress: CA209-9Y8 phase 2 trial of tumor treating fields (TTFs), nivolumab plus/minus ipilimumab for bevacizumab-naïve, recurrent glioblastoma

Safety of apixaban for venous thromboembolism prevention in patients with newly diagnosed glioblastoma

Response with combined dabrafenib and trametinib after BRAF inhibitor failure in BRAF-mutated glioblastoma: a case report

A phase I study of Suberoylanilide Hydroxamic Acid (SAHA) with Temsirolimus in children with newly diagnosed or progressive diffuse intrinsic pontine glioma (DIPG)

A series of patients (pts) with recurrent GBM (rGBM) treated with ABT-414, bevacizumab (Bev) and CCNU

Prospective selection of recurrent glioblastoma patients for tailored therapies. Results of an institutional experience.

Delta-24-RGD oncolytic adenovirus mediates anti-tumor effect in localized and disseminated AT/RT murine models

Combination of Tumor Treating Fields (TTFields) with lomustine (CCNU) and temozolomide (TMZ) in newly diagnosed glioblastoma (GBM) patients - a bi-centric analysis

Nivolumab vs bevacizumab in patients with recurrent glioblastoma: exploratory analysis of MGMT methylation status and baseline corticosteroid use